Introduction {#s1}
============

The main function of mitochondria is to convert the energy derived from nutrients into heat and ATP, a high-energy molecule exploited by the cell biochemical machineries. This process is carried out by the respiratory chain (RC) through oxidative phosphorylation (OxPhos) \[[@bst-2016-0085C1]\]. Respiration is performed by four multiheteromeric RC complexes, cI--IV, that transfer electrons from the NADH and FADH~2~, generated by intermediate metabolism, to molecular oxygen. Mammalian mitochondria have their own multicopy DNA (mitochondrial DNA, mtDNA), which encodes 13 subunits of the RC complexes I, III, IV, and V (complex II is only composed by 4 nucleus-encoded subunits), 22 transfer RNA, and 2 ribosomal RNA.

Mitochondria are double-membrane organelles, with the inner membrane folded into cristae where the respiratory complexes are housed. The electron flow is coupled to the translocation of protons across the inner mitochondrial membrane generating an electrochemical gradient, which is then exploited by RC complex V (cV or ATP synthase) to carry out the condensation of ADP and Pi into ATP \[[@bst-2016-0085C2]\].

Beside mtDNA-encoded proteins, the vast majority of the ∼1500 polypeptides forming the mitochondrial proteome is encoded by nuclear genes, which are translated in the cytosol into proteins and finally imported into the organelles. These proteins are required for a massive number of biological processes, such as replication, transcription, and translation of the mtDNA, formation and assembly of the RC complexes, fission--fusion of the mitochondrial network, signaling, and execution pathways (e.g. ROS production and apoptosis) \[[@bst-2016-0085C1]\].

Primary mitochondrial diseases can be attributed to mutations in both mitochondrial and nuclear genomes \[[@bst-2016-0085C3]\]. MtDNA mutations include homo- or heteroplasmic point mutations and heteroplasmic large-scale rearrangements. Examples of classical mtDNA-related diseases are mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers, neurogenic weakness, ataxia, and retinitis pigmentosa (NARP), Leigh syndrome (LS), Leber\'s hereditary optic neuropathy (LHON), sporadic progressive external ophthalmoplegia, Kearns--Sayre syndrome, and Pearson\'s syndrome \[[@bst-2016-0085C4]\].

Nuclear DNA-related mutations have been found in genes directly or indirectly related to the RC, including, among others, (i) proteins involved in mtDNA maintenance and/or replication machinery; (ii) structural subunits of the RC complexes; (iii) assembly factors of the respiratory complexes; and (iv) components of the translation apparatus \[[@bst-2016-0085C5]\].

Pathways to therapy {#s2}
===================

Currently, there is no treatment for mitochondrial diseases \[[@bst-2016-0085C6]\]. In the last few years, however, several potential therapeutic approaches have been proposed, and for some of them proof of efficacy has been provided in animal models, and testing their efficacy in humans is much awaited. These can be divided into two categories ([Table 1](#bst-2016-0085TB1){ref-type="table"}): (i) those acting on common pathways and thus, in principle, applicable to several disorders and (ii) those tailored to a specific disease. The first category includes the stimulation of mitochondrial biogenesis, the improvement of respiration efficiency by shaping the cristae, the bypass OxPhos defects by using xenogenes \[e.g. alternative oxidases (AOX) bypassing defects in cIII and cIV\], and the use of antioxidants and other compounds to scavenge toxic metabolites. The second group includes Adeno-associated viral (AAV)-mediated gene therapy approaches aimed at re-expressing the wild-type gene or other therapeutic genes (e.g. endonucleases to shift the heteroplasmy) in targeted tissues. Here, I will briefly review these strategies ([Table 2](#bst-2016-0085TB2){ref-type="table"}; for a more detailed review see ref. \[[@bst-2016-0085C7]\]). I will also summarize recent clinical trials, and the difficulties and challenges of translating a proof-of-principle experiment into clinics. Mitochondrial replacement therapy is discussed elsewhere \[[@bst-2016-0085C8]\]. Table 1Overview of the therapeutic strategies for primary mitochondrial diseasesAdvantagesDisadvantagesExamplesGeneral strategiesWide applicabilityPotentially cost-effectiveAddress common pathomechanismsOff-target effectsActivation of mitochondrial biogenesisRegulating execution pathways (apoptosis, autophagy, and fission/fusion)Shaping mitochondrial cristaeBypass of RC defects by using xenogenesUse of dNTPsTailored strategiesTargeted for a single diseasePotentially highly effectiveLimited to a single/few conditionsExpensiveAAV-mediated gene replacementSelective elimination of mutant mtDNA by ZNF or TALE nucleases

Non-tailored strategies {#s3}
=======================

Nucleotide metabolism {#s3a}
---------------------

Supplementation of deoxyribonucleosides has been used quite successfully in mouse models of mtDNA instability syndromes. This approach was highly effective in improving the biochemical and/or clinical defect *in vivo* in the *Tymp*^−/−^ mouse \[[@bst-2016-0085C9]\], a model of mitochondrial neuro-gastro-intestinal encephalomyopathy (MNGIE), and in the *Tk2*^−/−^ mouse, characterized by early-onset fatal encephalomyopathy \[[@bst-2016-0085C10]\]. *Tymp* encodes the cytosolic thymidine phosphorylase, which catalyzes the first step of thymidine and deoxyuridine catabolism; *Tk2* encodes mitochondrial thymidine kinase, which phosphorylates thymidine and deoxycytidine pyrimidine nucleosides to generate deoxythymidine monophosphate (dTMP) and deoxycytidine monophosphate (dCMP). Mutations in either enzymes lead to nucleotide imbalance and mtDNA instability, which can be rescued by the supplementation of deoxycytidine or tetrahydrouridine \[[@bst-2016-0085C9]\], an inhibitor of cytidine deaminase, in the case of the *Tymp*^−/−^ mouse model, and by dCMP + dTMP in the case of the *Tk2*^−/−^ mouse model \[[@bst-2016-0085C10]\].

Stimulation of mitochondrial biogenesis {#s3b}
---------------------------------------

Bioenergetic defects and reduced ATP synthesis are key features of mitochondrial diseases and increasing mitochondrial mass or activity can thus be beneficial. The transcriptional co-activator peroxisome proliferator-activated receptor-γ1 (PGC1) α is the master regulator of mitochondrial biogenesis. PGC1α interacts with and increases the activity of several transcription factors, including the nuclear respiratory factors (NRF1 and 2), which, in turn, control the expression of OxPhos-related genes, and the peroxisomal proliferator activator receptors (PPARs) α, β, and γ, which control the expression of genes related to fatty acids oxidation \[[@bst-2016-0085C11]\]. In addition, PGC1α is activated by either deacetylation by Sirtuin 1 (Sirt1) or phosphorylation by AMP-dependent kinase (AMPK), both of which can be modulated pharmacologically \[[@bst-2016-0085C12]\]. For instance, AMPK is activated by AICAR, an adenosine monophosphate analog, whereas Sirt1 is activated by increasing cellular levels of NAD^+^, a co-substrate in the deacetylation reaction. This latter effect can be achieved by (i) providing NAD^+^ precursors and (ii) inhibiting NAD^+^ consuming enzymes such as the poly(ADP) ribosyl-polymerase 1. The administration of AICAR, nicotinamide riboside (NR), a NAD^+^ precursor, or PARP inhibitors was able to robustly induce mitochondrial biogenesis and ameliorate the clinical phenotype of two mouse models of mitochondrial myopathy \[[@bst-2016-0085C13]--[@bst-2016-0085C15]\]. NR seems to be particularly attractive for testing in patients, because it effectively enhances Sirt1 activity and mitochondrial biogenesis but lacks the unwanted effects of other components of vitamin B3. Nicotinic acid, for instance, although effectively increasing mitochondrial biogenesis, induces flushing by activation of GPR109A receptor, which is not stimulated by NR \[[@bst-2016-0085C16]\], while nicotinamide has been reported as an inhibitor of histone deacetylases, including sirtuins \[[@bst-2016-0085C17]\].

Finally, bezafibrate, a pan-PPAR agonist, has also been used to stimulate PGC1α leading to a remarkable clinical amelioration of a mouse model of severe cIV deficiency \[[@bst-2016-0085C18]\]. These results, however, were not confirmed in later studies on different mouse models \[[@bst-2016-0085C14],[@bst-2016-0085C19]\], although the reasons for these discrepancies are unclear.

Overall, there is accumulating evidence in mouse models that boosting mitochondrial biogenesis can be an effective treatment for many mitochondrial diseases, independently of their genetic cause.

Improving mitochondrial shape {#s3c}
-----------------------------

Opa1 is a dynamin-like GTPase of the inner membrane playing a central role in cristae morphology. In humans, eight isoforms are generated by alternative splicing and processed by proteolytic cleavage by the two iAAA proteases, YME1 and OMA1, to form long (L-) and short (S-) forms, respectively. Increasing the expression of L-Opa1 improves respiration efficiency by increasing supercomplexes assembly \[[@bst-2016-0085C20]\] and protects *in vivo* from many insults such as ischemia--reperfusion, denervation-induced muscle atrophy, and OxPhos deficiency \[[@bst-2016-0085C21],[@bst-2016-0085C22]\]. Accordingly, the up-regulation of L-Opa1 by deleting Oma1 delays neuronal loss and prolongs lifespan of prohibitin 2 knockout mouse \[[@bst-2016-0085C23]\]. Interestingly, a significant correction of mitochondrial ultrastructure in the same pathological conditions, and independently of the genetic cause, has been obtained by using Szeto-Schiller (SS) peptides \[[@bst-2016-0085C24]\]. These are tripeptides able to penetrate cells and to accumulate in mitochondria, where they bind cardiolipin, a lipidic component of the inner mitochondrial membrane with an important role in regulating the RC activity and in shaping mitochondrial cristae. Although the mechanism of SS peptides is poorly understood, cardiolipin modulates Opa1 activity and oligomerization \[[@bst-2016-0085C25]\], and they may actually modulate Opa1.

Bypassing RC defects {#s3d}
--------------------

Xenogenes, single-peptide enzymes derived from yeast or low eukaryotes, have been used to bypass the block of the RC due to defects in specific complexes in cellular and *Drosophila* models. The rationale for using these non-proton-pumping enzymes is that they should re-establish the electron flow, thus reducing the accumulation of reduced intermediates and ROS production, and increase ATP production by allowing proton pumping at the non-affected complexes. The NADH reductase (Ndi1), which in the yeast *Saccharomyces cerevisiae* transfers electrons from NADH to coenzyme Q (CoQ), has been used to bypass cI defects \[[@bst-2016-0085C26],[@bst-2016-0085C27]\]. Similarly, AOX, which in various organisms transfers electrons from CoQ to molecular oxygen, has been used to bypass cIII and IV defects \[[@bst-2016-0085C28],[@bst-2016-0085C29]\]. A transgenic mouse overexpressing *AOX* has been produced and did not show any gross abnormality \[[@bst-2016-0085C30]\], but the possibility to use AOX to bypass OxPhos defects *in vivo* in mammals has not yet been demonstrated.

Disease-tailored strategies {#s4}
===========================

AAV vectors are currently the most widely used vectors for gene therapy in humans because of several advantages, including the fact that they remain episomic, thus reducing the risk of insertional mutagenesis \[[@bst-2016-0085C31]\] and that an ever-expanding number of natural and engineered serotypes targeting different tissues has been described \[[@bst-2016-0085C32]\]. Integration of natural adeno-associated viruses into oncogenes, such as cyclin A2, and telomerase reverse transcriptase, has recently been reported and associated with hepatocellular carcinomas, although no such association has been so far reported for recombinant AAV vectors \[[@bst-2016-0085C33]\]. AAV\'s main limitations are related to their limited cloning capacity (no more than 4.7 kb should be included between ITRs), and the difficulty to target more tissues at the same time, which is a critical point for multisystem diseases (such as, in many cases, mitochondrial diseases).

Therapies with AAVs can be aimed at expressing either the wild-type form of mutated genes or other therapeutic genes (e.g. xenogenes).

Gene replacement therapies {#s4a}
--------------------------

Hepatotropic AAV2/8 serotype was successfully used to express the wild-type form of mitochondrial sulfide di-oxygenase *Ethe1* in the liver of *Ethe1*^−/−^ mice, a model of ethylmalonic encephalopathy (EE), a highly severe mitochondrial disease due to impaired disposal of toxic hydrogen sulfide (H~2~S) and a poison for cytochrome *c* oxidase \[[@bst-2016-0085C34]\]. AAV2/8-*Ethe1* fully rescued enzyme activity, leading to efficient clearance of H~2~S from the bloodstream with a significant recovery of the profound cIV deficiency in the tissues and a striking prolongation of the lifespan \[[@bst-2016-0085C34]\]. The present study demonstrated that the selective re-expression of the missing gene into the liver was sufficient to induce a significant amelioration of the clinical phenotype in the mouse model, thus paving the way for using liver transplant for EE. The first child affected by EE was transplanted in Rome, Italy \[[@bst-2016-0085C35]\]. Eight months after the liver transplant, spectacular neurological improvement and achievements in psychomotor development were observed, accompanied by a remarkable amelioration of biochemical abnormalities.

Similarly, AAV2/8 has been used to treat the *Tymp*^−/−^ mouse model of the MNGIE disease \[[@bst-2016-0085C36]\], suggesting that gene therapy or liver transplant can be valuable options also for this disorder. An intravenous injection of AAV2/8 particles expressing human wild-type *TYMP* normalized dCTP and dTTP levels in plasma and tissues for up to 8 months of age. Finally, AAV2/8 was also successfully used to correct the liver-specific mtDNA depletion and to prevent ketogenic diet-induced cirrhosis in *MPV17*^−/−^ mice \[[@bst-2016-0085C37]\].

Although the AAV-based therapies summarized above were very effective in mice, extremely high costs for the production of the viral stocks and the rarity of the diseases prevented so far their application to the humans.

Shifting heteroplasmy {#s4b}
---------------------

Mitochondrially targeted restriction endonucleases have been used to shift heteroplasmy levels in cell lines with mutations in mtDNA and heteroplasmic mice \[[@bst-2016-0085C38],[@bst-2016-0085C39]\]. This approach can, however, be used only when a suitable restriction site is introduced by the mutation, as in the case of the NARP mutation, which creates a SmaI restriction site. However, the introduction of TALE and zinc finger nucleases (TALEN and ZFN) allowed to bypass this limitation by addressing an unspecific restriction enzyme (FokI) to specific sites in the genome through the assembly of appropriate ZFN or TALE modules \[[@bst-2016-0085C40],[@bst-2016-0085C41]\]. The main limitation of this approaches is that they both require quite large constructs not easily fitted into AAV vectors.

From bench to bedside {#s5}
=====================

Overview on the clinical trials {#s5a}
-------------------------------

Vitamins and food supplements (including CoQ, vitamins A and E, and lipoic acid) are normally used as a supportive therapy for mitochondrial disease \[[@bst-2016-0085C6]\], but no one can modify the disease course. Intrinsic difficulties, including the small cohorts of homogeneous patients available, the limited amount of data on the natural history of the diseases, and poor predictability of the outcome due to high variability, prevent solid trial design. However, several clinical trials, either open-label or randomized double-blind, are currently underway or have been recently completed ([Table 3](#bst-2016-0085TB3){ref-type="table"}) \[[@bst-2016-0085C42]\], but the outcome is often unclear because the results have never been reported. The majority of the trials are focused on the use of antioxidants, especially on patients affected by LHON and MELAS, which offer rather big cohorts. For instance, EPI-743, a *para*-benzoquinone analog, is being tested on different types of mitochondrial diseases, including LHON and LS, while a trial on Pearson\'s disease has been terminated for unclear reasons. KH176, a derivative of the antioxidant Trolox, is being tested on MELAS patients. RTA408, a triterpenoid compound increasing antioxidant defenses by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), is being tested on myopathic patients. Notably, in all these cases no preclinical data on animal models of mitochondrial disease have been collected to support the trial. CoQ~10~ and idebenone, a quinone analog of CoQ~10~, are among the very few cases, in which rather extensive studies have been carried out in patients so far. Idebenone was shown to ameliorate the rate of recovery in LHON patients with discordant visual acuity, especially when treated early in the disease course \[[@bst-2016-0085C43]\], and has been recently approved by EU for the treatment of this disease. Contrariwise, CoQ~10~, which is effective in some patients with the rare congenital CoQ~10~ deficiency, was shown to have little effect on other mitochondrial diseases \[[@bst-2016-0085C44]\].[](#bst-2016-0085TB3){ref-type="table"} Table 2Experimental therapies for mitochondrial diseasesTargeted pathwayCompoundsReferencesNucleotide metabolism• dCMP or tetrahydrouridine (inhibitor of cytidine deaminase)\[[@bst-2016-0085C9]\]• dCMP +  dTMP\[[@bst-2016-0085C10]\]PGC1α-dependent mitochondrial biogenesis• AICAR (via AMPK)\[[@bst-2016-0085C14]\]• Bezafibrate (via PPARs)\[[@bst-2016-0085C18]\]• NR (via Sirt1) or PARP inhibitors\[[@bst-2016-0085C13]\]Mitochondrial shaping• Increasing L-Opa1\[[@bst-2016-0085C21]\]• Inhibition of Oma1\[[@bst-2016-0085C23]\]• SS peptides\[[@bst-2016-0085C24]\]Bypassing OxPhos defects• Ndi1 (bypass for cI defects)\[[@bst-2016-0085C26],[@bst-2016-0085C27]\]• AOX (bypass for cIII/cIV defects)\[[@bst-2016-0085C28],[@bst-2016-0085C29]\]Shifting heteroplasmy• Restriction endonucleases\[[@bst-2016-0085C38],[@bst-2016-0085C39]\]• ZNF nucleases\[[@bst-2016-0085C40]\]• TALE nucleases\[[@bst-2016-0085C41]\]Elimination of toxic compounds• AAV-mediated gene therapy\[[@bst-2016-0085C34],[@bst-2016-0085C36]\]• Liver transplant\[[@bst-2016-0085C35]\] Table 3Examples of the clinical trials currently open or completed for mitochondrial diseasesTreatmentDiseaseTrial numberDesignTarget of interventionOutcomeCurrently open EPI-743Metabolism or mitochondrial disordersNCT01642056Randomized, double-blindROSOngoing BezafibrateMitochondrial myopathyNCT02398201Open-labelMitochondrial biogenesisOngoing RTA 408Mitochondrial myopathyNCT02255422Randomized, double- blindROS/NRF2Ongoing KH176MELASNCT02544217Randomized, double-blindROSOngoing scAAV2-ND4LHONNCT02161380Open-labelND4OngoingCompleted KetonesMELASNCT01252979Open-labelHeteroplasmyN/A [l]{.smallcaps}-ArginineMELASNCT01603446Open-labelNitric oxideImprovement in aerobic capacity and muscle metabolism IdebenoneLHONNCT00747487Randomized, double-blindROSNo recovery in visual acuity, but improvements in secondary end points (e.g. changes in visual acuity of the best eye at baseline) Coenzyme Q10Mitochondrial diseaseNCT00432744Randomized, double-blindROSN/A MTP-131Mitochondrial myopathyNCT02367014Randomized, double-blindCardiolipinN/A

Other compounds, with different mechanisms of action under clinical trials, include bezafibrate, MTP-131, ketones, and [l]{.smallcaps}-arginine \[[@bst-2016-0085C42]\]. In spite of the contradictory results in mice, a clinical trial with bezafibrate is recruiting patients. This was prompted by an increase in mitochondrial content observed in the skeletal muscle of bezafibrate-treated patients with carnitine palmitoyl transferase II defects \[[@bst-2016-0085C45]\]. A clinical trial with MTP-131 on patients with mitochondrial myopathies has been completed, but the results are not available yet. Ketones were shown to shift heteroplasmy in cellular models carrying mutations in mtDNA \[[@bst-2016-0085C46]\] and were tested on MELAS patients, but also in this case no results were reported. [l]{.smallcaps}-Arginine, a donor of nitric oxide thus acting on vessels tone, induced an improvement in aerobic capacity and muscle metabolism in MELAS patients \[[@bst-2016-0085C47]\].

Two clinical trials are being carried out using AAV vectors to allotopically express mitochondrial *ND4* in LHON patients. However, it is still highly debated if allotopically expressed proteins are really imported into the mitochondria and integrated into functionally active complexes \[[@bst-2016-0085C48]\].

Conclusions {#s5b}
-----------

Mitochondrial medicine is experiencing a period of vibrant development. Several strategies have been proposed and some proved to be efficient in cell or animal models, but their application into the clinics is still challenging. Although the need for high-quality clinical trials has been repeatedly invoked \[[@bst-2016-0085C49]\], the transfer of preclinical studies into clinics is far from being a linear and easy process. More extensive collaborations between basic research laboratories, pharmacology experts, and industrial partners will be needed in order to tackle these problems and move the field into a new era.
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